Benjamin T. Ristau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Benjamin T. Ristau has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Alexander Kutikov
Fox Chase Cancer Center, Philadelphia, PA, USA
4 shared publicationsDylan M. Buller
University of Connecticut School of Medicine, Farmington, CT, USA
4 shared publicationsRobert G. Uzzo
Division of Urologic Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania
4 shared publicationsMarc C. Smaldone
Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
3 shared publicationsPeter C. Albertsen
University of Connecticut School of Medicine, Farmington, CT, USA
3 shared publications- Alexander Kutikov
Fox Chase Cancer Center, Philadelphia, USA
2 shared publications
Latest Publications
- Open Access
Contemporary Management of Adrenal Tumors
Background/Objectives: Widespread use of high-resolution cross-sectional imaging has made the incidentally discovered adrenal mass a common clinical problem. Although most adrenal incidentalomas are non-functioning benign adenomas, clinicians must distinguish them from actionable pathology such as functional adenomas, adrenocortical carcinoma, and pheochromocytoma. This review outlines the contemporary diagnostic algorithm for adrenal incidentalomas and the main indications for surgical and medical intervention. Methods: We performed a narrative review of current society guidelines and of the primary literature underlying their recommendations on anatomic, biochemical, and surgical evaluation, comparing recommendations and evidence grades where guidelines differ. Results: Management is driven primarily by imaging phenotype, lesion size, and hormonal function. Unenhanced computed tomography attenuation ≤ 10 Hounsfield units is highly specific for a benign lipid-rich adenoma. Hormonal evaluation should exclude hypercortisolism in all patients and pheochromocytoma in all but asymptomatic patients with homogeneous, lipid-rich lesions, with testing for primary aldosteronism and androgen excess when clinically indicated. Minimally invasive adrenalectomy is standard for hormonally active benign adenomas and most pheochromocytomas, whereas open adrenalectomy remains preferred for suspected adrenocortical carcinoma that is large or locally invasive, to avoid tumor capsule rupture. Novel therapies, including peptide receptor radionuclide therapy, show efficacy in advanced disease. Conclusions: Society guidelines agree on most of the diagnostic pathway but diverge on surveillance of large benign lesions, interpretation of cortisol testing, and the surgical approach to suspected carcinoma. A standardized, multidisciplinary approach that recognizes these differences and the strength of the underlying evidence optimizes outcomes while preventing unnecessary procedures.
Open AccessContemporary Management of Adrenal Tumors
Background/Objectives: Widespread use of high-resolution cross-sectional imaging has made the incidentally discovered adrenal mass a common clinical problem. Although most adrenal incidentalomas are non-functioning benign adenomas, clinicians must distinguish them from actionable pathology such as functional adenomas, adrenocortical carcinoma, and pheochromocytoma. This review outlines the contemporary diagnostic algorithm for adrenal incidentalomas and the main indications for surgical and medical intervention. Methods: We performed a narrative review of current society guidelines and of the primary literature underlying their recommendations on anatomic, biochemical, and surgical evaluation, comparing recommendations and evidence grades where guidelines differ. Results: Management is driven primarily by imaging phenotype, lesion size, and hormonal function. Unenhanced computed tomography attenuation ≤ 10 Hounsfield units is highly specific for a benign lipid-rich adenoma. Hormonal evaluation should exclude hypercortisolism in all patients and pheochromocytoma in all but asymptomatic patients with homogeneous, lipid-rich lesions, with testing for primary aldosteronism and androgen excess when clinically indicated. Minimally invasive adrenalectomy is standard for hormonally active benign adenomas and most pheochromocytomas, whereas open adrenalectomy remains preferred for suspected adrenocortical carcinoma that is large or locally invasive, to avoid tumor capsule rupture. Novel therapies, including peptide receptor radionuclide therapy, show efficacy in advanced disease. Conclusions: Society guidelines agree on most of the diagnostic pathway but diverge on surveillance of large benign lesions, interpretation of cortisol testing, and the surgical approach to suspected carcinoma. A standardized, multidisciplinary approach that recognizes these differences and the strength of the underlying evidence optimizes outcomes while preventing unnecessary procedures.
- 30 June 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (4) , 511-517
Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy
- 30 June 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (4) , 511-517
Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy
- 19 May 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (11) , 1089-1090
Rare genitourinary cancers: Spotlight on an unmet need in urologic oncology
- 19 May 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (11) , 1089-1090
Rare genitourinary cancers: Spotlight on an unmet need in urologic oncology
- 12 March 2025
- Published by Elsevier in Urologic Clinics of North America
- Vol. 52 (2)
Contemporary Adrenal Pathophysiology, Workup, and Management
- 12 March 2025
- Published by Elsevier in Urologic Clinics of North America
- Vol. 52 (2)
Contemporary Adrenal Pathophysiology, Workup, and Management
- 28 February 2025
- Published by Elsevier in Urologic Clinics of North America
- Vol. 52 (2) , 217-227
Review of Adrenal Androgen Synthesis, Hypersecretion, and Blockade
- 28 February 2025
- Published by Elsevier in Urologic Clinics of North America
- Vol. 52 (2) , 217-227
Review of Adrenal Androgen Synthesis, Hypersecretion, and Blockade
- 28 February 2025
- Published by Elsevier in Urologic Clinics of North America
- Vol. 52 (2) , 297-303
Education and Advocacy for Patients with Adrenal Disorders
- 28 February 2025
- Published by Elsevier in Urologic Clinics of North America
- Vol. 52 (2) , 297-303
Education and Advocacy for Patients with Adrenal Disorders
- Open Access
- 22 November 2023
- Published by Elsevier in Urology Case Reports
- Vol. 51, 102611
Incidental detection of pheochromocytoma during workup for symptomatic aortic stenosis: A case report and management discussion
- 22 November 2023
- Published by Elsevier in Urology Case Reports
- Vol. 51, 102611
Open AccessIncidental detection of pheochromocytoma during workup for symptomatic aortic stenosis: A case report and management discussion
- 1 September 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (3) , 444-445
Editorial Comment
- 1 September 2023
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 210 (3) , 444-445
Editorial Comment
- Open Access
- 1 January 2023
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 16, 49-64
Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction
Locally and regionally advanced renal cell carcinoma (RCC) can recur at high rates even after visually complete resection of primary disease. Both targeted therapies and immunotherapies represent potential agents that might help reduce recurrence of RCC in these patients. This paper reviews the current body of evidence defining their potential impact and examines the large Phase III randomized clinical trials that have been performed to assess the safety and efficacy of these systemic therapies in the adjuvant setting. Given that the findings from these trials have been predominantly negative, this paper also explores the role of other potential adjuvant agents, including single and combination agent targeted therapies and immunotherapies, whose use is currently limited to metastatic RCC. Finally, the use of radiation therapy and the use of advanced imaging modalities in RCC are also considered.
- 1 January 2023
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 16, 49-64
Open AccessAdjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction
Locally and regionally advanced renal cell carcinoma (RCC) can recur at high rates even after visually complete resection of primary disease. Both targeted therapies and immunotherapies represent potential agents that might help reduce recurrence of RCC in these patients. This paper reviews the current body of evidence defining their potential impact and examines the large Phase III randomized clinical trials that have been performed to assess the safety and efficacy of these systemic therapies in the adjuvant setting. Given that the findings from these trials have been predominantly negative, this paper also explores the role of other potential adjuvant agents, including single and combination agent targeted therapies and immunotherapies, whose use is currently limited to metastatic RCC. Finally, the use of radiation therapy and the use of advanced imaging modalities in RCC are also considered.
- Open Access
- 10 November 2022
- Published by Elsevier in Urology Case Reports
- Vol. 45, 102277
Resolution of manic symptoms following unilateral adrenalectomy in patient with primary bilateral macronodular adrenal hyperplasia
- 10 November 2022
- Published by Elsevier in Urology Case Reports
- Vol. 45, 102277
Open AccessResolution of manic symptoms following unilateral adrenalectomy in patient with primary bilateral macronodular adrenal hyperplasia